Ovid Therapeutics Q2 EPS $(0.18) Beats $(0.20) Estimate, Sales $75.00K Beat $50.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Ovid Therapeutics reported Q2 losses of $(0.18) per share, beating the analyst consensus estimate of $(0.20) by 10 percent. This is a 14.29 percent increase over losses from the same period last year. The company also reported quarterly sales of $75.00 thousand, beating the analyst consensus estimate of $50.00 thousand by 50.00 percent.
August 04, 2023 | 3:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ovid Therapeutics reported better than expected Q2 results with both EPS and sales beating estimates. The losses per share also improved compared to the same period last year.
Ovid Therapeutics reported better than expected Q2 results which is generally a positive signal for the stock. The company's losses per share also improved compared to the same period last year, indicating improved financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100